Cadila Pharmaceuticals is a multinational research based pharmaceutical group in India with more than 6 decades of experience. Company's integrated operations covers entire gamut from manufacturing products ranging from API's-Intermediates, finished formulations, OTC-Food Supplements, Biotechnology Products and pharmaceutical Machinery. Cadila Pharmaceuticals manufacturing facilities are approved by most stringent International bodies like WHO-GMP, UK-MHRA, USFDA-API, TGA-Australia, and AIFA-Italy. International operation of Cadila Pharmaceuticals is spread across 58 countries including Americas, Japan, Asia, CIS and Africa.
History
Cadila Laboratories
In 1951 Indravadan A Modi had quit his job as a chemist in a Mumbai firm to start Cadila Laboratories with childhood friendRamanbhai Patel. The company that started in a rented bungalow with a capital of Rs 25,000 and achieved a turnover of around Rs 1.25 lakh in its first year of operation had come a long way.
1995: Demerger of Cadila Laboratories
The Modi and Patel families decided to split the business in 1995, two entities were formed - Cadila Pharmaceuticals Ltd and Cadila Healthcare. Rajiv Modi and I A Modi worked closely to run Cadila Pharma, now considered one of the largest privately-held pharma companies in the country, with revenues of around Rs 1200 crore.
Operations
Cadila Pharmaceuticals has its formulation manufacturing facilities at Dholka, Gujarat ; Samba, Jammu and at Addis Ababa and 2 API manufacturing facilities are located at Ankleshwar, Gujarat. The manufacturing facility at Dholka and the API unit at Ankleshwar in Gujarat are USFDA-certified; the overseas manufacturing facility at Ethiopia is the WHO - cGMP compliant facility.
Research
Cadila Pharmaceuticals has established a dedicated R&D facility, spread over 1,05,000 sq. ft. area at Dholka, Gujarat, India which is manned by 300 scientists. The company has five IND dossiers filed with the USFDA for pulmonary tuberculosis, lung cancer, prostate cancer, bladder cancer and melanoma. The company has submitted ten ANDAs. Cadila Pharmaceuticals has connections with various institutions for research; Department of Biotechnology, UDSC, New Delhi; IISc, Bangalore; Lala Ram Sarup Institute of TB & Respiratory diseases, New Delhi; RRL, Jammu; CSIR, New Delhi; CDRI, Lucknow; Advanced Transfusion Medicine Research Foundation, Ahmedabad; National Institute of Immunology, New Delhi; Institute of Microbial Technology, Chandigarh; Talwar Research Foundation, New Delhi and Trieste, Italy.
Products and services
Cadila Pharmaceuticals is the only Indian manufacturer of natural Streptokinase and Hyaluronic Acid products. The company was also the first in the world to introduce Rabeprazole in IV form – ‘Rabeloc’. In 2009, the world’s first boosted-Rifampicin fixed-dose combination for the treatment of Tuberculosis – ‘Risorine’ and world's first drug combination for prevention of Cardiovascular Diseases – ‘’ were introduced by Cadila Pharmaceuticals. For the patients suffering from Non Small Cell Lung Cancer, company has recently introduced ‘Mycidac-C’ - first in the class active immunotherapy as well as drug targeting Desmocollin. Some of the top brands of the company are Aciloc, Envas, Calcirol, Haem Up, Vasograin, Tricort, Fludac, Rabiloc, Trigan-D, Mycobutol and Sepsivac.
Alliances
In 2019, Cadila Pharmaceuticals formed a partnership with Norwegian start-up, Serca Pharmaceuticals to develop new treatment for heart patients.
Awards and Recognition
Most Trusted Companies of 2008, Sara Media and Zee Business WorldStar Packaging Award, 2018 TISS LeapVault CLO Award, 2019 Observenow Future of Workplace Award, 2019 Great Place to Work Certified, 2020
